A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009) Meeting Abstract

  

Authors:	O'Cearbhaill, R.; Sill, M.; Duong, H.; Waggoner, S.; Grisham, R.; Backes, F.; Mannel, R.; Tanyi, J.; Powell, M.; Mathews, C.; Ghamande, S.; Mcnally, L.; Olawaiye, A.; Bender, D.; Duska, L.; Lankes, H.; Zamarin, D.; Schilder, R.; Bookman, M.; Aghajanian, C.
Abstract Title:	A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)
Meeting Title:	IGCS 2023 Annual Meeting
Journal Title:	International Journal of Gynecological Cancer
Volume:	33
Issue:	Suppl. 4
Meeting Dates:	2023 Nov 5-7
Meeting Location:	Seoul, South Korea
ISSN:	1048-891X
Publisher:	Lippincott Williams & Wilkins
Date Published:	2023-11-01
Start Page:	A4
Language:	English
ACCESSION:	WOS:001262421600038
DOI:	10.1136/ijgc-2023-IGCS.5
PROVIDER:	wos
Notes:	Meeting Abstract: PO005LBA/#1579 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/218642